Bristol-Myers Squibb Company Stock
Findings
- The distance to the 52-week high is 9.7%.
- Strongest group: Momentum, 3 of 5 positive. Weakest: Oscillators, 0 of 2.
- The 30-day volatility of 31.7% sits in the upper third of the 416 titles in the universe.
Signal groups
Describes past price action, not a recommendation. As of October 26, 2026 at 08:03 AM, computed from the closing prices of the last trading day.
Key figures
- 1 day
- -2.4%
- 4 weeks
- -2.2%
- 52 weeks
- +43.2%
- Volatility 30 days
- 31.7%
- Max. decline 52 weeks
- -16.8%
- Distance to 52-week high
- -9.7%
- Sharpe ratio 1 year
- 1.38
In comparison
- The volatility sits in the upper third of the 44 titles in the Healthcare sector.
- The volatility sits in the middle third of the 133 titles on US exchanges.
The 16 signals
Each signal is one indicator. Tap it to see what it measures and what it currently shows for Bristol-Myers Squibb Company.
EMA CrossoverCautious
For Bristol-Myers Squibb Company, the fast moving average has crossed below the slow one. By this indicator's definition that corresponds to a downtrend, a description of past price action.
Compares a fast moving average to a slow one. When the fast is above the slow, the trend is positive. Period settings are automatically calibrated per asset class.
Read in the glossaryMA Trend Filter (200-day)Positive
Checks whether the price is above or below its 200-day moving average, a look at the long-term trend.
ADX DirectionMixed
Shows whether upward or downward moves dominate in the trend whose strength the ADX measures (+DI versus -DI).
Read in the glossaryADX Trend Strength17.9Mixed
ADX stands at 17.9, a moderate trend.
ADX does not measure direction, only how pronounced a trend is, regardless of whether it points up or down. We use it as a filter: only above a certain value does a trend count as strong enough to give other signals more weight. Direction itself comes from the separate ADX Direction signal.
Read in the glossaryRegression Intercept1.02Cautious
Fits a straight line through the closing prices of a fixed window and compares its level today with its level a few days earlier. A rising line describes an uptrend.
RSI (14)51.0Mixed
RSI stands at 51.0, in the neutral zone between 45 and 55. Upward and downward moves over the last 14 trading days are roughly balanced.
The Relative Strength Index measures the ratio of upward to downward price movements over the last 14 trading days (Wilder smoothing) on a scale of 0 to 100. Our neutral zone is 45 to 55, tighter than the classic 30/70 band, outside of it the methodology reads the RSI as overbought or oversold.
Read in the glossaryMACD+0.6%Positive
MACD stands at +0.6%, above the positive threshold, momentum over recent weeks is upward.
MACD measures the gap between two exponentially smoothed averages. Our periods are 12/20/9 instead of the common 12/26/9, and the signal threshold is normalized to 0.3% of the current price rather than the raw MACD value, which keeps the threshold comparable across different price levels.
Read in the glossaryRate of Change-1.7%Cautious
Bristol-Myers Squibb Company is -1.7% lower than 63 trading days ago, a negative medium-term price change.
Rate of Change measures the percentage price change over the last 63 trading days, roughly one quarter, a medium-term window, not a short-term daily or weekly read.
Read in the glossary52-Week High90.3%Positive
Bristol-Myers Squibb Company trades at 90.3% of its 52-week high, near the highest point of the last 252 trading days.
Measures how close the current price is to its highest point over the last 252 trading days, roughly one year. A value near 100% means the price is at or near its yearly high.
Read in the glossaryMomentum Oscillator+3.8%Positive
Bristol-Myers Squibb Company shows an accelerating upward move at +3.8%, recent price gains are larger than before.
Checks whether the recent price movement is accelerating or decelerating. Unlike Rate of Change, this indicator measures the pace of the change, not the change itself.
Read in the glossaryWilliams %R-28.4Mixed
Williams %R stands at -28.4, a neutral position. The price is in the middle of the recent trading range, without extremes in either direction.
Williams %R shows where the current price sits within the high-low range of the last 14 trading days. We read it as contrarian: a favorable signal only fires on a confirmed turn upward out of the oversold zone, not on any low value by itself, an extreme oversold reading alone never produces a cautious signal for us.
Read in the glossaryStochastic %K71.6Mixed
Stochastic %K stands at 71.6, currently without a confirmed crossover in either direction.
The Stochastic oscillator shows where the closing price sits within the recent trading range. A low or high value alone isn't enough for us: a signal only fires once %K and %D are both below 20 (or above 80) and %K is crossing upward (or downward), a confirmed turning point rather than a raw level.
Read in the glossaryVIX Level19.4Mixed
The VIX derives the expected fluctuation of the next 30 days from options on the S&P 500. It describes the market environment and is the same for every title.
Read in the glossaryVIX Rate of Change-2.7%Mixed
Measures how much the VIX has changed over the last trading days. A fast rise stands for quickly growing expected fluctuation. The same for every title.
Read in the glossaryHY SpreadCautious
The yield premium of high-yield bonds over government bonds, a gauge of how the credit market prices default risk. It describes the market environment and is the same for every title.
Read in the glossaryRelative Strength0.95Cautious
Bristol-Myers Squibb Company stands at 0.95, below the reference index, price performance over the period was weaker than the reference index's.
Compares price performance over a medium-term period against a broad stock market index as a reference. A value above 1.0 means stronger performance than the reference index, below 1.0 means weaker.
Analyze Bristol-Myers Squibb Company in your own portfolio
edgio computes what you see here for Bristol-Myers Squibb Company for every position in your portfolio, and gets in touch when something turns.
- Watch Bristol-Myers Squibb Company: score and 16 signals on your watchlist, up to 5 titles
- Your own portfolio with up to 3 positions: score, risk and spread
- Weekly overview by email
- An email as soon as the score of Bristol-Myers Squibb Company turns
- Signal history of Bristol-Myers Squibb Company in hindsight
- Backtest: how the levels would have come through past crises with Bristol-Myers Squibb Company
- Risk budget with a loss limit, up to 50 positions
7 days of Pro free, then Free automatically. No credit card.
How the score comes about
- 0116 signals per title
Trend, momentum, oscillators and the market environment (VIX, credit market), computed every trading day after the close from the closing prices.
- 02One score from 0 to 100
A weighted average, not a majority vote. From 70 Positive, 40 to 69 Mixed, below 40 Cautious.
- 03Tested in hindsight
The same methodology was tested in 12 time windows from 2014 to 2025, on 64 portfolios.
We do not publish the weighting of the individual signals. Methodology in detail
About Bristol-Myers Squibb Company
Bristol Myers Squibb is a research-based biopharmaceutical company discovering and commercializing therapies in oncology, hematology, immunology, and cardiovascular diseases. Commercial blockbusters such as the anticoagulant Eliquis and the immuno-oncology agent Opdivo generate the largest share of current revenue. To offset legacy patent expirations, the company is advancing its growth portfolio of newly launched drugs including Camzyos, Sotyktu, and CAR-T cell therapies. Bristol Myers Squibb distributes medicines globally and invests heavily in late-stage clinical pipelines for targeted combination treatments. Headquarters are located in Princeton, New Jersey.
Technical reading
Technical analysis for Bristol-Myers Squibb Company stock (BMY), trend direction, momentum strength and risk metrics based on 16 quantitative signals, updated daily.
Trend. 1 of 5 trend signals read positive. ADX at 17.9 indicates a moderate trend. The price is above the 200-day moving average.
Momentum. 3 of 5 momentum signals read positive. RSI at 51.0 is in the neutral range.
Risk Metrics. 30-day volatility at 31.7%. price within 10% of its 52-week high. Sharpe Ratio at 1.38 indicates a good risk-adjusted return over 12 months.
Market Environment. VIX at 19.4 indicates normal expected market volatility. The high-yield spread signal reads cautious.
Sector Context. 52-week return of 43.2% is above the Healthcare sector average of 25.9%. Ranked #34 of 44 Healthcare titles by signal score.
Questions about Bristol-Myers Squibb Company
How does Bristol-Myers Squibb Company stand according to the edgio signals?
The signal score of Bristol-Myers Squibb Company is 46 out of 100, which is the state Mixed. 4 of 16 signals are positive. As of October 26, 2026 at 08:03 AM.
What is the RSI of Bristol-Myers Squibb Company?
The RSI (14) of Bristol-Myers Squibb Company is 51.0. Upward and downward moves are roughly balanced. At edgio the neutral zone is 45 to 55.
Is this a forecast or a recommendation?
No. The signals describe past price action and the market environment. They do not predict the future and do not consider your personal situation. You make your own decisions.
How often is the score computed?
Every trading day after the close. The page shows the state of the latest computation.
In the Healthcare sector
Each cell is one title, sorted by signal score. Bristol-Myers Squibb Company is highlighted.
Compare with another title
Two titles side by side, with the values of this page.
More Healthcare titles
Notes
The information presented does not constitute investment advice and should not be construed as a solicitation to buy or sell financial instruments. Past performance is not a reliable indicator of future results. Any investment decision should be based on your own research and, where appropriate, professional advice. Marvin Waraschitz, founder of edgio, currently holds no position in BMY.
The values are computed algorithmically from public market data (closing prices, VIX, credit spreads). Logos by Elbstream. Methodology & full disclaimer
Methodology & Background
- RSI Aktien: Was der Relative-Strength-Index misst, was er nicht misst und warum die Standardschwellen oft falsch eingesetzt werden (Deutsch) →
- EMA Crossover erklärt: Wie das Signal funktioniert und welche Perioden Tests bestanden haben (Deutsch) →
- 16 Signale, 148 Aktien, 12 Jahre: Was unsere Backtests wirklich zeigen (Deutsch) →